| LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders |
2020-04-15 |
| Axxam–ERS Genomics: CRISPR technology, 202004– license ww €na for drug discovery services of Axxam |
2020-04-02 |
| MolMed–Asahi Glass: investment, 202003– cash tender offer €240m for 463.5m shares at €0.518/share by AGC Inc ANNOUNCED |
2020-03-17 |
| Autolus–MolMed: viral vectors, 202003– collab multi-year developm + supply of viral vectors by MolMed for T cell cancer therapies |
2020-03-05 |
| BIA Separations–Univ Zagreb: purification technology, 202002– commercial license + collab developm of virus + viral vector immunoaffinity purification |
2020-02-19 |
| Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
| Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic RnD bispecific Abs for dermatology using WuXiBody antibody technology |
2020-01-09 |
| Eyevensys–Pontifax: investment, 202001 financing round Series B totalling $30m incl existing + co-investor Pontifax |
2020-01-08 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Doc Generici–Mérieux: investment, 2019 investment by Mérieux Participations 3 Fund |
2019-12-31 |
| Vico Therapeutics–Pontifax: investment, 2019Q4–202007 financing round Series A totalling €27m incl co-investor Pontifax |
2019-12-31 |
| Seer–aMoon: investment, 201912 financing round Series D totalling $55m incl lead investor aMoon Fund |
2019-12-17 |
| Biological Industries (IL)–Sartorius: investment, 201912 acquisition of just over 50% for €45m in cash with option to acquire further 20% |
2019-12-05 |
| Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |
| Grifols–Shanghai RAAS: plasma products + diagnostics, 201911c– strategic alliance in China incl share swap |
2019-11-13 |
| Shanghai RAAS–Grifols: investment, 201911c acquisition 26.2% share in Shanghai RAAS via share swap as part of strategic alliance |
2019-11-13 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| Pepticom–Chartered Group: investment, 201910 Series A investment of $5m by the Chartered Group |
2019-10-24 |
| Menarini–BlueBee: bioinformatics, –201909 collab developm of MSBiosuite using BlueBee genomics data platoform |
2019-09-19 |
| GenomSys–Club degli Investitori: investment, 201909 financing round Series A totalling CHF9.3m incl co-investor Club degli Investitori |
2019-09-16 |
| Healthy.io–SEVERAL: investment, 201909 financing round Series C $60m led by Corner Ventures |
2019-09-12 |
| Genenta Science–Bormioli Group: investment, 201909 3rd financing round totalling €13.2m incl co-investor Bormioli family |
2019-09-11 |
| Genenta Science–Fumagalli Group: investment, 201909 3rd financing round totalling €13.2m incl co-investor Fumagalli family |
2019-09-11 |
| Genenta Science–Qianzhin Investment Management: investment, 201909 3rd financing round totalling €13.2m incl co-lead investor QZ |
2019-09-11 |
| Genenta Science–Rovati Group: investment, 201909 3rd financing round totalling €13.2m incl co-lead investor Fidim |
2019-09-11 |
| Genenta Science–SEVERAL: investment, 201909 3rd financing round €13.2m led by Qianzhan Investment Management + Fidim |
2019-09-11 |
| Univ Florence–Bruker: NMR spectrometer, 201908– supply expected first customer for new 1.2 GHz NMR spectrometer |
2019-08-26 |
| MDClone–aMoon: investment, 201908 financing round Series B totalling $26m incl lead investor aMoon |
2019-08-22 |
| MDClone–Lightspeed Venture Partners: investment, 201908 financing round Series B totalling $26m incl co.investor Lightspeed Venture Partners |
2019-08-22 |
| MDClone–Orbimed: investment, 201908 financing round Series B totalling $26m incl co.investor OrbiMed Israel Partners |
2019-08-22 |
| MDClone–SEVERAL: investment, 201908 financing round Series B $26m led by aMoon + incl OrbiMed + Lightspeed Venture Partners |
2019-08-22 |
| SP Industries–i-Dositecno: filling solutions, 201908– collab product integration to offer complete aseptic vial/syringe fill-finish lines |
2019-08-13 |
| Evogene–Leucadia: investor conference, 201908 supply service Evogene presents at Jefferies 2019 Industrials Conference NYC |
2019-08-06 |
| Ako med–Curetis: Unyvero system, 201907– distribution excl 3y Unyvero A50 system + cartridges in Serbia + Bosnia + North Macedonia + Montenegro |
2019-07-30 |
| Breath Therapeutics–Zambon: investment, 201907 acquisition €140m + €360m milestones by Zambon |
2019-07-25 |
| Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight |
2019-07-23 |
| BiomX–SEVERAL: investment, 201907–201910 listing at NYSE via SPAC merger with $60m in trust account |
2019-07-17 |
| Bayer–Evogene: plant genomics, 201907 collaboration amendment to refocus on genome editing target discovery for corn diseases |
2019-07-16 |
| Sanifit–Alta Life Sciences: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Alta Life Sciences |
2019-06-26 |
| Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners |
2019-06-26 |
| Sanifit–Columbus Venture Partners: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Columbus Venture Partners |
2019-06-26 |
| Sanifit–Consilium: public relations, 201906 service existent by CSC |
2019-06-26 |
| Sanifit–Forbion: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Forbion Capital Partners |
2019-06-26 |
| Sanifit–Gilde Investment: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Gilde Healthcare |
2019-06-26 |
| Sanifit–HealthEquity: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor HealthEquity |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Sanifit–Ysios Capital: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Ysios Capital |
2019-06-26 |
| BMS–Catalent: investment, 201906– acquisition of BMS manufacturing facility in Anagni Italy by Catalent |
2019-06-19 |
| Gamida Cell–Lonza: cell therapy contract manufacturing, 201906– supply multi-year future commercial production of omidubicel by Lonza in Geleen (NL) |
2019-06-19 |
| Ona Therapeutics–Asabys Partners: investment, 201905 seed financing €1.5m from Sabadell Asabys Fund |
2019-05-21 |
| Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona |
2019-05-20 |
| Philogen–Consilium: public relations, 201905 service existent by CSC |
2019-05-13 |
| Philogen–SEVERAL: investment, 201905 financing round €62m from existing + new private investors |
2019-05-13 |
| Cutech (IT)–Symrise: investment, 201905 acquisition of Cutech Srl by Symrise |
2019-05-06 |
| Devicare–SEVERAL: investment, 201905– crowdfunding compaign via Capital Cell platform |
2019-05-06 |
| Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC |
2019-05-03 |
| Aidoc–SEVERAL: investment, 201904 financing round Series B $27m led by Square Peg Capital |
2019-04-17 |
| Aidoc–Square Peg Capital: investment, 201904 financing round Series B totalling $27m incl lead investor Square Peg Capital |
2019-04-17 |
| Agomab Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| Menarini–Curetis: molecular diagnostics, 201903– distribution excl long-term of Unyvero platform + cartridges in Europe by Menarini Diagnostics |
2019-03-26 |
| Rocket Pharmaceuticals–MolMed: gene therapy, 201903– collab expansion developm + manufacture of lentiviral vectors by MolMed for three new indications |
2019-03-13 |
| SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding |
2019-03-07 |
| BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund |
2019-02-20 |
| BiomX–MacDougall Biomedical Communications: public relations, 201902 service existent by MacDougall |
2019-02-20 |
| BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al |
2019-02-20 |
| Denothex–Optimapharm: investment, 201902 acquisition of Denothex Ltd by Optimapharm |
2019-02-06 |
| Grifols–Rigel: fostamatinib, 201901– collab + license $30m upront + $297.5m milestones + royalties all indications in Europe + Turkey |
2019-01-23 |
| Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel |
2019-01-21 |
| UroGen–JPMorgan Chase: investor conference, 201901 supply service UroGen Pharma presents at JP Morgan Healthcare Conference 2019 |
2019-01-10 |
| Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences |
2019-01-09 |
| Biond Biologics–Celgene: investment, 201901 financing round Series B totalling $17m incl co-investor Celgene Corp |
2019-01-08 |
| Biond Biologics–Harel: investment, 201901 financing round Series B totalling $17m incl co-lead investor Harel Insurance & Finance Group |
2019-01-08 |
| Biond Biologics–Israel Biotech Fund: investment, 201901 financing round Series B totalling $17m incl co-lead investor Israel Biotech Fund |
2019-01-08 |
| Biond Biologics–SBI Holdings: investment, 201901 financing round Series B totalling $17m incl co-investor SBI JI Innovation Fund |
2019-01-08 |
| Biond Biologics–SEVERAL: investment, 201901 financing round Series B $17m co-led by Israel Biotech Fund + Harel Insurance & Finance Group |
2019-01-08 |
| Melio Health–Kanoar Ventures: investment, 2019c seed financing round for IMU Biosciences incl investor Kfund |
2019-01-01 |
| Altheia Science–SEVERAL: investment, 201812 financing round Series A final closing €7.7m ($8.3m) bringing total round to €17m ($19.3m) |
2018-12-19 |
| Mestrelab Research–Bruker: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership |
2018-12-13 |
| JnJ–BiomX: biomarker discovery, 201812– collab using XMarker microbiome-based marker discovery platform for IBD therapeutics PDx |
2018-12-12 |
| Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA |
2018-12-05 |
| Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA |
2018-12-05 |
| Oryzon Genomics–Citigroup: investor conference, 201812 supply service Oryzon attends Citi Global Healthcare Conference NY |
2018-12-05 |
| Lonza–Chaim Sheba Medical Center: cell therapy manufacturing technology, 201811 collab existent to evaluate + test Cocoon technology |
2018-11-19 |
| Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries |
2018-11-15 |
| Oryzon Genomics–Leucadia: investor conference, 201811 supply service Oryzon attends Jefferies London Healthcare Conference 2018 |
2018-11-14 |
| Newron–EU (govt): credit, 201810– EIB/EFSI loan up to €40m to develop new CNS drugs |
2018-10-30 |
| Galecto–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital |
2018-10-26 |
| Gamida Cell–SEVERAL: investment, 201810 IPO $50m+$7.5m with 6.25m+937.5k ordinary shares at $8/sahre at Nasdaq Global Market |
2018-10-26 |
| Oryzon Genomics–SEVERAL: investment, 201810 private placement €13m w 4.96m new common shares at €2.62/share |
2018-10-26 |
| Minoryx–SEVERAL: investment, 201809 financing round Series B €21.3m led by Fund+ with SFPI + SRIW + Sambrinvest + all Series A investors |
2018-09-26 |
| Altheia Science–SEVERAL: investment, 201809 financing round Series A 1st closing €9.3m ($11m) incl AurorA-TT + private investors |
2018-09-25 |
| Almirall–Evotec: drug discovery services, 201809– collab RnD therapies for dermatological diseases |
2018-09-17 |
| Menarini–Lunaphore: staining technology, 201809– collab Menarini Diagnostics to market LabSat Frozen tissue staining solution |
2018-09-09 |
| Grifols–EU (govt): credit, 201809–2028 loan €85m from European Investment Bank |
2018-09-07 |
| Teva–Prilenia: pridopidine, 201809 establishment of Prilenia with acquisition of pridopidine from Teva |
2018-09-01 |
| Merck (DE)–GlucoMe: digital health, 201808– collab digital diabetes management project in Vietnam |
2018-08-22 |
| Molecular Discovery–Lead Molecular Design: mass spectrometry s/w, 201808 distribution existent of MetaSite + MassMetaSite et al by Molecular Discovery |
2018-08-04 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 5 6 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
